Practice

Patient Support Programs Associated With Greater Likelihood of Controlled AS

April 17th 2018

By Kelly Davio

Canadian patients who receive brand-name adalimumab (Humira) to treat ankylosing spondylitis (AS) are eligible for a patient support program, provided by drug maker AbbVie, that includes personalized services such as coaching phone calls before and after initiating treatment.

Oncologist Sees Biosimilars Playing a Role in the Oncology Care Model

April 12th 2018

By Kelly Davio

Article

Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, told The Center for Biosimilars® in an interview that, as his practice has begun to implement the Oncology Care Model, it has moved 100% of its patients to biosimilar filgrastim, Zarxio, from the reference filgrastim, Neupogen.

Upadacitinib Superior to Adalimumab in Phase 3 Trial in RA

April 11th 2018

By Samantha DiGrande

Article

AbbVie reports that the trial of 15 mg of orally-administered, once-daily upadacitinib met its primary endpoints, with 71% of patients achieving 20% improvement based on American College of Rheumatology criteria (ACR20), and 29% achieving clinical remission.

Trastuzumab Improves PFS in Rare Endometrial Cancer in Phase 2 Trial

April 11th 2018

By Kelly Davio

Article

Researchers demonstrated that trastuzumab increased progression-free survival (PFS) in patients with uterine serous carcinoma.

Sanofi Launches Follow-On Insulin Lispro, Admelog

April 9th 2018

By The Center for Biosimilars Staff

Article

Sanofi’s list prices for Admelog are approximately 15% lower than the originator Humalog’s prices.

Study Suggests That Two AEs May Predict Improved Outcomes With Bevacizumab

April 9th 2018

By Kelly Davio

Article

A recent study concludes that both hypertension and proteinuria, which are considered to be interrelated with the pharmacological action of bevacizumab, have the potential to indicate greater likelihood of therapeutic efficacy.

Study: No Difference in MI Prevalence Among Patients Receiving Intravitreal Bevacizumab

April 4th 2018

By The Center for Biosimilars Staff

Article

Data suggest that intravitreal bevacizumab increases the risk of thromboembolism, and some studies have raised the possibility of a link between bevacizumab and myocardial infarction (MI), while other studies did not find such a relationship.

NHS Prepares for October 2018 Arrival of Biosimilar Adalimumab

April 4th 2018

By Kelly Davio

Article

In a briefing to regional committees, the United Kingdom's National Health Service (NHS) urged commissioners to begin planning to use the best-value adalimumab option beginning in October 2018, when Amgen’s EU-authorized biosimilar, Amgevita, becomes available.

Long-Term Adalimumab Provides Sustained Benefits in Axial Spondyloarthritis

April 3rd 2018

By Kelly Davio

Article

A recent study provides the final long-term efficacy and safety results from the phase 3 ABILITY-1 trial’s open-label extension in patients with nonradiographic axial spondyloarthritis, which show that the anti–tumor necrosis factor agent adalimumab (Humira) provided sustained clinical and functional improvements through 3 years.

Anti-VEGF Drugs Not Associated With Increased Risk of AEs in Eye Diseases

March 28th 2018

By Samantha DiGrande

Article

Last week, an overview of systematic reviews and meta-analyses investigating systemic adverse events associated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatments was published in JAMA Ophthalmology.